ReviewFrontiers in immunology2026
Therapeutic cancer vaccines: navigating clinical translation and multimodal synergy.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Over the past decades, the field of cancer treatment has been revolutionized by cancer immunotherapy. With therapeutic cancer vaccines (TCVs) are emerging as a promising strategy capable of eliciting potent and lasting T cell responses against cancer cells. While theoretically potent, the translation of TCVs into consistent clinical success remains an evolving challenge. Therefore, this review provides a comprehensive overview of TCVs, traversing from fundamental TCVs concepts, epitope spreading, antigen selection, and delivery platforms, to the current clinical landscape. We specifically examine the transition from monotherapy to innovative combination regimens and propose a translational concept of the strategic utility of TCVs in targeting minimal residual disease (MRD). Despite significant immunogenic potential, the clinical impact of TCVs is currently constrained by the manufacturing hurdles, immunosuppressive tumor microenvironment (TME), patient heterogeneity, and evaluation of outcomes. By addressing these barriers through rational therapeutic approaches and optimized patient selection, TCVs may offer a promising pathway for integration into future clinical paradigms to improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.